Anti-kappa type light chain antibody and application thereof

Abstract

The invention discloses an antibody for resisting a kappa-type light chain or a reagent and a kit for detecting the kappa-type light chain, and relates to the field of antibodies. The anti-kappa type light chain antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for kappa type light chain detection, and has good affinity or activity.

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, and in particular to an anti-κ light chain antibody and applications thereof. Background Art

[0002] The light chain of immunoglobulin is composed of approximately 214 amino acid residues, usually does not contain carbohydrates, and has a molecular weight of approximately 24kD. Each light chain contains two cyclic peptides composed of intrachain disulfide bonds. Light chains can be divided into κ type (Kappa type) and λ type (Lambda type). The type on each light chain can only belong to one of the two types, but not both. The difference between κ type and λ type is mainly manifested in the difference in amino acid sequence and disulfide chain position. The ratio of κ type / λ type in different species is not the same. The ratio of κ type:λ type in normal human serum is about 2:1. From the study of gene expression in some species, it is known that the rearrangement of Kappa gene occurs earlier than Lambda gene, which may be one of the reasons why κ type appears more and pairs with heavy chain. Light chains are small molecular proteins that can freely pass through the glomerular basement membrane and are reabsorbed in the renal tubules back into the blood circulation. Therefore, only a small amount of light chains are present in the urine of normal people. When immunoglobulin synthesis is abnormally activated, the synthesis rate of heavy and light chains increases rapidly, resulting in a serious excess of light chains.

[0003] Among patients with multiple myeloma, about 20% of patients only secrete free light chains (FLC), and 50% have both monoclonal immunoglobulins and monoclonal urinary light chains. The former have a poor prognosis. Quantitative detection of different types of light chain content is helpful in diagnosing diseases such as macroglobulinemia and connective tissue diseases (such as rheumatoid arthritis and systemic lupus erythematosus). In addition, light chains in the blood may also increase in infection, acute and chronic hepatitis, cirrhosis, etc., but generally manifested as an increase in κ and λ at the same time; patients with kidney disease, diabetes, etc. may also have an increase in κ and λ in their urine. Therefore, the detection of κ-type light chains is of great significance for early diagnosis, prognosis, medication guidance, and pathogenesis research.

[0004] Immunological detection methods are one of the best choices for detecting light chain polypeptides. Immunological detection methods such as colloidal gold immunochromatography, fluorescent immunochromatography, biochemical immunoturbidimetry, etc. are all based on the specific reaction of antibodies and antigens, and use labeled substances (such as colloidal gold, fluorescence, latex, etc.) to amplify and display the detected signal. Similar immunological detection methods include radioimmunoassay and chemiluminescence.

[0005] The above-mentioned immunological detection methods all require antibodies against κ-type light chains. Therefore, those skilled in the art have a strong demand for anti-κ-type light chain antibodies with good performance. Summary of the invention

[0006] The present application provides an anti-κ light chain antibody or an antigen-binding fragment thereof, which provides an important source of raw materials for the detection of κ light chains and has good activity or affinity.

[0007] In order to achieve the above-mentioned object, according to one aspect of the present invention, an anti-κ type light chain antibody or an antigen-binding fragment thereof is provided, wherein the anti-κ type light chain antibody or the antigen-binding fragment thereof comprises three complementary determining regions having a heavy chain variable region of any one of the amino acid sequences SEQ ID NO: 20 and 21 and three complementary determining regions having a light chain variable region of any one of the amino acid sequences SEQ ID NO: 24, 25 and 26.

[0008] In order to achieve the above object, according to a second aspect of the present invention, an anti-κ light chain antibody or an antigen-binding fragment thereof is provided, wherein the anti-κ light chain antibody or the antigen-binding fragment thereof comprises the following complementarity determining regions:

[0009] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0010] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0011] HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3;

[0012] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 4 or 17;

[0013] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and

[0014] LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 6 or 18, or consists of the same.

[0015] In order to achieve the above-mentioned purpose, according to the third aspect of the present invention, an anti-κ light chain antibody or an antigen-binding fragment thereof is provided, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 20 and 21; and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 24, 25, and 26.

[0016] In order to achieve the above-mentioned purpose, according to the fourth aspect of the present invention, an anti-κ light chain antibody or an antigen-binding fragment thereof is provided, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NO:22 and 23; the amino acid sequence of the light chain is shown in any one of SEQ ID NO:27, 28 and 29.

[0017] In order to achieve the above object, according to the fifth aspect of the present invention, an antibody conjugate is provided, wherein the antibody conjugate comprises the above anti-κ light chain antibody or an antigen-binding fragment thereof.

[0018] In order to achieve the above object, according to the sixth aspect of the present invention, a reagent or a kit is provided, wherein the reagent or the kit comprises the above-mentioned anti-κ light chain antibody or its antigen-binding fragment or the above-mentioned antibody conjugate.

[0019] In order to achieve the above-mentioned purpose, according to the seventh aspect of the present invention, a method for detecting κ-type light chains is provided, comprising: a) contacting the above-mentioned anti-κ-type light chain antibody or its antigen-binding fragment, antibody conjugate, or reagent or kit with the κ-type light chains in the sample to be detected under conditions sufficient for an antibody / antigen binding reaction to occur to form an immune complex; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the antigen in the test sample.

[0020] In order to achieve the above object, according to the eighth aspect of the present invention, a nucleic acid is provided, wherein the nucleic acid encodes the above anti-κ light chain antibody or an antigen-binding fragment thereof.

[0021] In order to achieve the above object, according to the ninth aspect of the present invention, a vector is provided, wherein the vector comprises the above nucleic acid.

[0022] In order to achieve the above object, according to the tenth aspect of the present invention, a cell is provided, wherein the cell comprises the above nucleic acid, vector or expresses the above anti-κ light chain antibody or antigen-binding fragment thereof.

[0023] In order to achieve the above object, according to the eleventh aspect of the present invention, a method for preparing the above anti-κ light chain antibody or antigen-binding fragment thereof is provided, the method comprising culturing the above cells.

[0024] In order to achieve the above-mentioned purpose, according to the twelfth aspect of the present invention, there is provided a use of the above-mentioned anti-κ light chain antibody or its antigen-binding fragment, antibody conjugate, reagent or kit in the preparation of a product for detecting κ light chain. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0026] Figure 1The results of reducing SDS-PAGE of Anti-KAPPA 12G3 Rmb1 to Anti-KAPPA 12G3 Rmb6 are shown. DETAILED DESCRIPTION

[0027] In the first aspect, an embodiment of the present invention provides an anti-κ light chain antibody or an antigen-binding fragment thereof, wherein the anti-κ light chain antibody or the antigen-binding fragment thereof comprises three complementary determining regions having a heavy chain variable region of any one of the amino acid sequences SEQ ID NO: 20 and 21 and three complementary determining regions having a light chain variable region of any one of the amino acid sequences SEQ ID NO: 24, 25, and 26.

[0028] It should be noted that HCDR1, HCDR2 and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, HCDR3 of the same heavy chain variable region defined in the anti-κ light chain antibody or its antigen-binding fragment described in the first aspect, and LCDR1, LCDR2 and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, LCDR3 of the same light chain variable region defined in the anti-κ light chain antibody or its antigen-binding fragment described in the first aspect.

[0029] For example, the HCDR1, HCDR2, and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the heavy chain variable region shown in SEQ ID NO:20; the LCDR1, LCDR2, and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the light chain variable region shown in SEQ ID NO:24.

[0030] In the present invention, the term "antibody" is used in the broadest sense and may include full-length monoclonal antibodies, bispecific or multispecific antibodies, and chimeric antibodies, so long as they exhibit the desired biological activity.

[0031] In the present invention, the term "complementarity determining region", "CDR" or "CDRs" refers to the highly variable region of the heavy and light chains of immunoglobulins, and refers to the region containing one or more or even all of the major amino acid residues that play a role in the binding of an antibody or antigen-binding fragment to its recognized antigen or epitope. In a specific embodiment of the present invention, CDRs refers to the highly variable region of the heavy and light chains of the antibody.

[0032] In the present invention, the heavy chain complementarity determining region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determining region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0033] The definition methods of CDR are well known in the art, and the CDR definition methods include: Kabat definition, Chothia definition, IMGT definition, Contact definition and AbM definition. As described herein, "Kabat definition" refers to the definition system described in Kabat et al., US Pept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" refers to Chothia et al., J Mol Biol 196: 901-917 (1987). There are other CDR definition methods that may not strictly follow one of the above schemes, but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or extended based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below, and the definitions in different documents are slightly different. Given the variable region amino acid sequence of an antibody, a person skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods not limited to Table 1 also belong to the scope of protection of the present disclosure.

[0034] Table 1: CDR Definition 1

[0035]

[0036]

[0037] 1 The numbering of all CDR definitions in Table 1 is based on the Kabat numbering system (see below), with the amino acid numbering on the heavy chain represented by "H+number" and the amino acid numbering on the light chain represented by "L+number". One of ordinary skill in the art can unambiguously map the Kabat numbering system to any variable region sequence without relying on any experimental data other than the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., U.S. Patent. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0038] 2 "AbM" as used in Table 1 with a lowercase "b" refers to CDRs defined by Oxford Molecular's "AbM" antibody modeling software.

[0039] 3If both H35A and H35B are absent, CDR-H1 ends at position 35; if only H35A is present, CDR-H1 ends at position 35A; if both H35A and H35B are present, CDR-H1 ends at position 35B.

[0040] 4 If both H35A and H35B are absent, CDR-H1 ends at position 32; if only H35A is present, CDR-H1 ends at position 33; if both H35A and H35B are present, CDR-H1 ends at position 34.

[0041] 5 If both H35A and H35B are absent, CDR-H1 ends at position 33; if only H35A is present, CDR-H1 ends at position 34; if both H35A and H35B are present, CDR-H1 ends at position 35.

[0042] According to an embodiment of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one system or a combination of multiple systems of Kabat, Chothia, IMGT, AbM or Contact.

[0043] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Kabat system.

[0044] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the Chothia system.

[0045] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the IMGT system.

[0046] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by the AbM system.

[0047] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a Contact system.

[0048] In some optional embodiments of the present invention, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM or Contact systems.

[0049] According to an embodiment of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 defined by the Kabat, Chothia, AbM or IMGT systems are as follows:

[0050] CDR Kabat AbM IMGT Chothia HCDR1 H31~H35 H26~H35 H26~H33 H26~H32 HCDR2 H50~H65 H50~H58 H51~H57 H52~H56 HCDR3 H95~H102 H95~H102 H93~H102 H95~H102 LCDR1 L24~L34 L24~L34 L27~L32 L24~L34 LCDR2 L50~L56 L50~L56 L50~L51 L50~L56 LCDR3 L89~L97 L89~L97 L89~L97 L89~L97

[0051] According to an embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises the following complementarity determining regions:

[0052] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0053] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0054] HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3;

[0055] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 4 or 17;

[0056] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and

[0057] LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 6 or 18, or consists of the same.

[0058] In a second aspect, an embodiment of the present invention provides an anti-κ light chain antibody or an antigen-binding fragment thereof, wherein the anti-κ light chain antibody or the antigen-binding fragment thereof comprises the following complementary determining regions:

[0059] HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1;

[0060] HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2;

[0061] HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3;

[0062] LCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 4 or 17;

[0063] LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and

[0064] LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 6 or 18, or consists of the same.

[0065] According to an embodiment of the present invention, the HCDRs and LCDRs are defined by the Kabat system.

[0066] In the present invention, the "framework region" or "FR" region includes the heavy chain framework region and the light chain framework region, and refers to the region other than the CDR in the heavy chain variable region and the light chain variable region of the antibody; wherein the heavy chain framework region can be further subdivided into adjacent regions separated by CDR, including HFR1, HFR2, HFR3 and HFR4 framework regions; the light chain framework region can be further subdivided into adjacent regions separated by CDR, including LFR1, LFR2, LFR3 and LFR4 framework regions.

[0067] In the present invention, the heavy chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0068] In an optional embodiment, the anti-κ type light chain antibody or antigen-binding fragment thereof of the first aspect or the second aspect further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4;

[0069] The HFR1 comprises / is SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto;

[0070] The HFR2 comprises / is SEQ ID NO:8 or an amino acid sequence having at least 80% identity thereto;

[0071] The HFR3 comprises / is SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto;

[0072] The HFR4 comprises / is SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto;

[0073] The LFR1 comprises / is SEQ ID NO:11 or an amino acid sequence having at least 80% identity thereto;

[0074] The LFR2 comprises / is SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto;

[0075] The LFR3 comprises / is SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto;

[0076] The LFR4 comprises / is SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto.

[0077] It should be noted that, in other embodiments, the amino acid sequences of the framework regions of the anti-κ light chain antibodies or antigen-binding fragments thereof provided by the present invention may be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the above-mentioned corresponding framework regions (SEQ ID NO: 7, 8, 9, 10, 11, 12, 13 or 14).

[0078] In an optional embodiment, the HFR2 comprises / is represented by the amino acid sequence shown in SEQ ID NO:19.

[0079] In an optional embodiment, the anti-κ light chain antibody or antigen-binding fragment thereof has a KD≤10 -7 M, KD≤10 -8 M, KD≤10 -9 M, KD≤10 -10 M, KD≤10 -11 M, KD≤10 -12 M, KD≤10 -13 M, KD≤10 -14 M or KD≤10 -15 M binds with affinity to kappa-type light chains.

[0080] There are many methods for determining antibody affinity (KD), which can be divided into thermodynamic detection methods, kinetic detection methods and dynamic equilibrium detection methods according to the detection principle. Among them, thermodynamic detection methods are commonly used, such as isothermal titration calorimetry (ITC); kinetic detection methods are commonly used, such as surface plasmon resonance (SPR) and biomembrane interferometry (BLI); dynamic equilibrium detection methods are commonly used, such as enzyme-linked immunosorbent assay (ELISA).

[0081] In an alternative embodiment, KD is determined using a kinetic assay; optionally, surface plasmon resonance, for example by using a kinetic assay such as Biosensor system of the system.

[0082] In a third aspect, an embodiment of the present invention provides an anti-κ light chain antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 20 and 21, and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 24, 25, and 26.

[0083] In an optional embodiment, the heavy chain variable region and the light chain variable region described in the first aspect or the third aspect are selected from any combination of the following:

[0084]

[0085]

[0086] In an optional embodiment, the antibody or antigen-binding fragment thereof described in the first aspect, the second aspect or the third aspect comprises any combination of the following heavy chain variable regions and light chain variable regions:

[0087] combination Heavy chain variable region Light chain variable region 1 SEQ ID NO:20 SEQ ID NO:24 2 SEQ ID NO:20 SEQ ID NO:25 3 SEQ ID NO:20 SEQ ID NO:26 4 SEQ ID NO:21 SEQ ID NO:24 5 SEQ ID NO:21 SEQ ID NO:25 6 SEQ ID NO:21 SEQ ID NO:26 .

[0088] In an optional embodiment, the anti-κ light chain antibody or antigen-binding fragment thereof described in the first aspect, the second aspect or the third aspect further comprises a constant region.

[0089] In an alternative embodiment, the constant region includes a heavy chain constant region and / or a light chain constant region.

[0090] In an optional embodiment, the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments.

[0091] In an alternative embodiment, the heavy chain constant region includes CH1 of IgG, a hinge region of IgG, CH2 of IgM, CH3 of IgM and / or CH4 of IgM.

[0092] In an alternative embodiment, the IgG is selected from IgG1, IgG2, IgG3 or IgG4.

[0093] In an alternative embodiment, the light chain constant region is selected from a kappa-type or a lambda-type light chain constant region.

[0094] In an alternative embodiment, the constant region is derived from a species of cow, horse, dairy cow, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock or human.

[0095] In an alternative embodiment, the species origin of the constant region is mouse.

[0096] In an optional embodiment, the heavy chain constant region sequence (CH) is as shown in SEQ ID NO:15, and the light chain constant region (CL) sequence is as shown in SEQ ID NO:16.

[0097] It should be noted that, in other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the above-mentioned constant region (SEQ ID NO: 15 or 16).

[0098] In an optional embodiment, the antigen-binding fragment is selected from any one of F(ab)2, F(ab')2, Fab', Fab, Fv and scFv of the antibody.

[0099] The antigen-binding fragments of the above antibodies usually have the same binding specificity as the antibodies from which they are derived. It is easy for those skilled in the art to understand based on the contents described in the present invention that the antigen-binding fragments of the above antibodies can be obtained by methods such as enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds. Based on the structure of the complete antibody disclosed in the present invention, those skilled in the art can easily obtain the above antigen-binding fragments.

[0100] The antigen-binding fragments of the above antibodies can also be synthesized by recombinant genetic techniques also known to those skilled in the art or by, for example, an automatic peptide synthesizer, such as those sold by Applied BioSystems and the like.

[0101] In a fourth aspect, the present invention provides an anti-κ light chain antibody or an antigen-binding fragment thereof, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 22 and 23, and the amino acid sequence of the light chain is shown in any one of SEQ ID NOs: 27, 28, and 29.

[0102] In an optional embodiment, the antibody or antigen-binding fragment thereof described in the first aspect, the second aspect, the third aspect or the fourth aspect comprises any combination of the following heavy chains and light chains:

[0103] combination Heavy chain Light chain 1 SEQ ID NO:22 SEQ ID NO:27 2 SEQ ID NO:22 SEQ ID NO:28 3 SEQ ID NO:22 SEQ ID NO:29 4 SEQ ID NO:23 SEQ ID NO:27 5 SEQ ID NO:23 SEQ ID NO:28 6 SEQ ID NO:23 SEQ ID NO:29

[0104] In a fifth aspect, the present invention provides an antibody conjugate, wherein the antibody conjugate comprises the above-mentioned anti-κ light chain antibody or an antigen-binding fragment thereof.

[0105] In an optional embodiment, the above-mentioned antibody conjugate further includes biotin or a biotin derivative conjugated to the anti-κ light chain antibody or the antigen-binding fragment thereof.

[0106] In an optional embodiment, the antibody conjugate further comprises a label coupled to the anti-κ light chain antibody or the antigen-binding fragment thereof.

[0107] In an optional embodiment, the above-mentioned marker refers to a class of substances with properties that can be directly observed by the naked eye or detected or detected by an instrument, such as luminescence, color development, radioactivity, etc., through which qualitative or quantitative detection of the corresponding target can be achieved.

[0108] In an alternative embodiment, the label includes but is not limited to fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent agents and nanoparticle labels.

[0109] In actual use, those skilled in the art can select a suitable marker according to the detection conditions or actual needs. No matter which marker is used, it belongs to the protection scope of the present invention.

[0110] In an optional embodiment, the fluorescent dye is not limited to fluorescein dyes and their derivatives (for example, including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc. or their analogs), rhodamine dyes and their derivatives (for example, including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc. or their analogs), Cy series dyes and their derivatives (for example, including but not limited to Cy2, Cy3, Cy3B, Cy3.5, Cy3.7, Cy3.8, Cy3.9, Cy3.10, Cy3.11, Cy3.12, Cy3.13, Cy3.14, Cy3.15, Cy3.16, Cy3.17, Cy3.18, Cy3.19, Cy3.20, Cy3.21, Cy3.22, Cy3.23, Cy3.24, Cy3.25, Cy3.26, Cy3.27, Cy3.28, Cy3.29, Cy3.30, Cy3.31, Cy3.32, Cy3.33, Cy3.34, Cy3.35, Cy3.36, Cy3.37, Cy3.38, Cy3.39, Cy3.40, Cy3.41, Cy3.42, Cy3.43, Cy3.44, Cy3.45, Cy3.46, Cy3.47, Cy3.48, Cy3.49, Cy3.50, Cy3.51, Cy3.52, Cy3.53, Cy3.54, Cy3.55, Cy3.56, Cy3.57, Cy3.58, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.59, Cy3.5 y5, Cy5.5, Cy3, etc. or their analogs), Alexa series dyes and their derivatives (for example, including but not limited to AlexaFluor350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750, etc. or their analogs) and protein dyes and their derivatives (for example, including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), pre-chlorophyll protein (preCP), etc.).

[0111] In alternative embodiments, the enzyme includes, but is not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and 6-phosphoglucose deoxygenase.

[0112] In an optional embodiment, the radioactive isotopes include but are not limited to 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu and 18F.

[0113] In an optional embodiment, the chemiluminescent reagent includes but is not limited to luminol and its derivatives, lucigenin, crustacean fluorescein and its derivatives, bipyridine ruthenium and its derivatives, acridinium esters and their derivatives, dioxetanes and their derivatives, lophanes and their derivatives, and peroxyoxalates and their derivatives.

[0114] In an optional embodiment, the nanoparticle markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0115] In alternative embodiments, the colloid includes, but is not limited to, colloidal metals, disperse dyes, dye-labeled microspheres, and latex.

[0116] In an alternative embodiment, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0117] In an optional embodiment, the colloidal metal is colloidal gold.

[0118] In an optional embodiment, the above-mentioned antibody conjugate further includes a solid phase carrier coupled to the anti-κ light chain antibody or the antigen-binding fragment thereof.

[0119] In an alternative embodiment, the solid support is selected from microspheres, plates and membranes.

[0120] In an optional embodiment, the solid phase carrier includes but is not limited to magnetic microspheres, plastic microspheres, plastic microparticles, microwell plates, glass, capillaries, nylon and nitrocellulose membranes.

[0121] In an alternative embodiment, the plastic particles are nanospheres, such as latex.

[0122] In a sixth aspect, the present invention provides a reagent or a kit, wherein the reagent or the kit comprises the above-mentioned anti-κ light chain antibody or its antigen-binding fragment or the above-mentioned antibody conjugate.

[0123] As mentioned above, the anti-κ type light chain antibody or its antigen binding fragment in some embodiments or examples of the present invention can effectively bind to the κ type light chain, therefore, the reagent or kit containing the anti-κ type light chain antibody or its antigen binding fragment can effectively detect the κ type light chain qualitatively or quantitatively. The reagent or kit provided by the present invention can be used, for example, for detection involving the use of the specific binding properties of the κ type light chain and its antibody, such as immunoblotting and immunoprecipitation. As mentioned above, the anti-κ type light chain antibody or its antigen binding fragment in some embodiments or examples of the present invention has a higher binding activity or affinity with the κ type light chain, therefore, the reagent or kit containing the anti-κ type light chain antibody or its antigen binding fragment has a higher detection sensitivity or specificity.

[0124] In a seventh aspect, the present invention provides a method for detecting κ-type light chains, comprising: a) contacting the above-mentioned anti-κ-type light chain antibody or its antigen-binding fragment, antibody conjugate, reagent or kit with the κ-type light chain in a sample to be detected to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence of the antigen in the test sample;

[0125] In an optional embodiment, the immune complex further comprises a second antibody, which binds to the anti-κ light chain antibody or antigen-binding fragment thereof.

[0126] In an optional embodiment, the immune complex further comprises a second antibody, which binds to a κ light chain.

[0127] In an eighth aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned anti-κ light chain antibody or its antigen-binding fragment.

[0128] In a ninth aspect, the present invention provides a vector containing the above-mentioned nucleic acid molecule.

[0129] In a tenth aspect, the present invention provides a cell containing the above-mentioned vector.

[0130] In an eleventh aspect, the present invention provides a method for preparing an anti-κ light chain antibody or an antigen-binding fragment thereof, comprising: culturing the cells as described above.

[0131] In a twelfth aspect, the present invention provides use of the above-mentioned anti-κ light chain antibody or its antigen-binding fragment, antibody conjugate or the above-mentioned reagent or kit in the preparation of a product for detecting κ light chain.

[0132] In a thirteenth aspect, the present invention provides use of the above-mentioned antibody or antigen-binding fragment thereof, antibody conjugate or the above-mentioned reagent or kit in detecting κ-type light chains or indicating κ-type light chain-related diseases.

[0133] In a fourteenth aspect, the present invention provides a method for indicating a κ light chain-related disease in a subject, comprising:

[0134] a) contacting the above-mentioned antibody or antigen-binding fragment thereof, antibody conjugate, or the above-mentioned reagent or kit with a κ-type light chain in a sample from a subject to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and

[0135] b) detecting the presence of the immune complex, wherein the presence of the complex indicates the presence or status of a kappa light chain-associated disease in the subject.

[0136] In an alternative embodiment, the immune complex further comprises a second antibody that binds to the antibody or antigen-binding fragment thereof.

[0137] In an optional embodiment, the immune complex further comprises a second antibody, which binds to a κ light chain.

[0138] In an optional embodiment, the κ-type light chain-related disease in the thirteenth aspect or the fourteenth aspect is selected from multiple myeloma, macroproteinemia, connective tissue disease, infection, acute and chronic hepatitis, cirrhosis, kidney disease, diabetes and the like.

[0139] Based on the amino acid sequence of the anti-κ type light chain antibody or its antigen-binding fragment disclosed in the present invention, those skilled in the art can easily think of using genetic engineering technology or other technologies (chemical synthesis, recombinant expression) to prepare the anti-κ type light chain antibody or its antigen-binding fragment, for example, separating and purifying the anti-κ type light chain antibody or its antigen-binding fragment from the culture product of a recombinant cell that can recombinantly express the anti-κ type light chain antibody or its antigen-binding fragment as described in any of the above items, which is easy to achieve for those skilled in the art. Based on this, no matter what technology is used to prepare the anti-κ type light chain antibody or its antigen-binding fragment of the present invention, it belongs to the protection scope of the present invention.

[0140] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0141] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used for the practice or testing of the preparations or unit doses herein, some methods and materials are now described. Unless otherwise stated, the techniques adopted or considered herein are standard methods. Materials, methods and examples are illustrative and non-restrictive only.

[0142] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a skilled artisan. This technique is fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (PCR: The Polymerase Chain Reaction) (Academic Press, Inc., 1987). Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0143] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0144] Example 1 Preparation of Anti-KAPPA 12G3 Monoclonal Antibody

[0145] In this example, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. MagExtractor-RNA extraction kit was purchased from TOYOBO. BD SMART TM The RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen. Primer synthesis and gene sequencing were completed by Invitrogen. The hybridoma cell line secreting the Anti-KAPPA 12G3 monoclonal antibody was prepared in this laboratory and revived for future use.

[0146] (1) Antibody gene preparation

[0147] mRNA was extracted from the hybridoma cell line secreting Anti-KAPPA12G3 monoclonal antibody, and the DNA product was obtained by RT-PCR. The product was inserted into the pMD-18T vector after A addition reaction with rTaq DNA polymerase and transformed into DH5α competent cells. After the colonies grew, the Heavy Chain and Light Chain gene clones were taken respectively, and 4 clones each were sent to a gene sequencing company for sequencing.

[0148] (2) Sequence analysis of the variable region gene of Anti-KAPPA12G3 antibody

[0149] The gene sequences obtained by the above sequencing were placed in the kabat antibody database for analysis, and the VNTI11.5 software was used for analysis to determine that the genes amplified by the heavy chain and light chain primer pairs were correct. Among the gene fragments amplified by the Light Chain, the VL gene sequence was 321 bp, and there was a 57 bp leader peptide sequence in front of it; in the gene fragments amplified by the Heavy Chain primer pair, the VH gene sequence was 354 bp, belonging to the VH1 gene family, and there was a 57 bp leader peptide sequence in front of it.

[0150] (3) Construction of recombinant antibody expression plasmid

[0151] pcDNA TM 3.4 vector is a recombinant antibody eukaryotic expression vector constructed, which has introduced multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector; according to the sequencing results of the antibody variable region genes in the above pMD-18T, the VL and VH gene-specific primers of the antibody were designed, with HindIII, EcoRI restriction sites and protective bases at both ends, respectively, and the 0.70kb Light Chain gene fragment and the 1.38kb Heavy Chain gene fragment were amplified by the PCR amplification method.

[0152] The Heavy Chain and Light Chain gene fragments were double-digested with HindIII / EcoRI, and the 3.4A vector was double-digested with HindIII / EcoRI. After the fragments and vectors were purified and recovered, the Heavy Chain gene and the Light Chain gene were respectively connected to the 3.4A expression vector to obtain the recombinant expression plasmids of Heavy Chain and Light Chain, respectively.

[0153] 2. Recombinant Antibody Production

[0154] Resuscitate HEK293 cells in advance and subculture them to 200 ml system to make the cell density reach 3-5×10 6 cells / ml, the cell density reaches the selected antibody concentration and cells, and the cell viability is >95%; the cells are washed by centrifugation and re-dissolved with culture medium, and the cell density is adjusted to 2.9×10 6 cells / ml, wash the cells, and re-dissolve them with culture medium, and use it as a cell diluent. Prepare plasmid DNA and transfection reagent diluents with culture medium respectively. Add the transfection reagent diluent to the plasmid DNA diluent, mix well and let stand at room temperature for 15 minutes; slowly add the mixture to the cell diluent within 1 minute, mix well and take samples to count, record and observe the viability of the cells after transfection, and place them in a 35℃ constant temperature incubator for culture, with a speed of 120rmp and a CO2 content of 8%. Centrifuge and collect samples after 13 days. The centrifuged supernatant was affinity purified using a proteinA affinity chromatography column. Take 6ug layer of purified antibodies for reducing SDS-PAGE, and the electrophoresis is shown in the figure. After reducing SDS-PAGE, two bands are shown, one Mr is 50KD (heavy chain) and the other Mr is 28KD (light chain).

[0155] The obtained antibody was named Anti-KAPPA 12G3Rmb1. Anti-KAPPA 12G3Rmb1 was mutated to obtain a mutant antibody. The sequences of the heavy chain (H) and light chain (L) of the above antibody are shown in the following table:

[0156] Table 2 Antibody sequences

[0157] Antibody Name Heavy chain Light chain Anti-KAPPA12G3Rmb1 SEQ ID NO:22 SEQ ID NO:27 Anti-KAPPA12G3Rmb2 SEQ ID NO:22 SEQ ID NO:28 Anti-KAPPA12G3Rmb3 SEQ ID NO:22 SEQ ID NO:29 Anti-KAPPA 12G3Rmb4 SEQ ID NO:23 SEQ ID NO:27 Anti-KAPPA12G3Rmb5 SEQ ID NO:23 SEQ ID NO:28 Anti-KAPPA12G3Rmb6 SEQ ID NO:23 SEQ ID NO:29

[0158] Example 2 Performance testing of antibodies

[0159] 1. Affinity Analysis

[0160] The purified antibody was diluted in advance, and the KAPPA antigen (purchased from biospacific, catalog number J82700478) was diluted in gradients. The binding and dissociation curves of the antigen and antibody were tested on the Biacore 8K+ device using a CM5 chip that had been pre-coupled with goat anti-mouse IgG. The instrument automatically fitted the affinity constant, binding rate, and dissociation rate. The results showed that the affinity of the antibodies Anti-KAPPA12G3Rmb1~Anti-KAPPA 12G3Rmb6 to the KAPPA antigen was 1.0×10 -12 M≤KD<1.0×10 - 7 M, and the affinity between the control antibody and KAPPA antigen is better than that of the control antibody. (KD represents the equilibrium dissociation constant, i.e., the affinity constant; ka represents the binding rate; kd represents the dissociation rate)

[0161] 2. Activity identification

[0162] The coating solution (main component NaHCO3) was used to dilute KAPPA antigen (purchased from biospacific, product number J82700478) to 2ug / ml, 100uL per well, and incubated at 4°C overnight; the next day, the cells were washed twice with washing solution (main component Na2HPO4+Nacl), and patted dry; blocking solution (20% BSA+80% PBS) was added, 120uL per well, and incubated at 37°C for 1h, and patted dry; the diluted purified antibody was added Add the antibody and control antibody, 100uL / well, 37℃, 30min; wash 5 times with washing solution, pat dry; add goat anti-mouse IgG-HRP, 100uL per well, 37℃, 30min; wash 5 times with washing solution, pat dry; add colorimetric solution A (50uL / well), add colorimetric solution B (50uL / well), 10min; add stop solution, 50uL / well; read the OD value at 450nm (reference 630nm) on the microplate reader.

[0163] Note: Solution A (main ingredients: citric acid + sodium acetate + acetanilide + urea peroxide); Solution B (main ingredients: citric acid + EDTA·2Na + TMB + concentrated HCL); Stop solution (EDTA·2Na + concentrated H2SO4)

[0164] Table 3 Activity data

[0165] Concentration (ng / ml) 125.00 62.50 31.25 15.63 7.81 0.00 Comparison 1.268 0.734 0.419 0.255 0.101 0.025 Anti-KAPPA 12G3Rmb1 1.996 1.439 0.814 0.464 0.282 0.032 Anti-KAPPA 12G3Rmb2 1.956 1.422 0.825 0.427 0.254 0.032 Anti-KAPPA 12G3Rmb3 1.936 1.437 0.836 0.443 0.236 0.036 Anti-KAPPA 12G3Rmb4 1.947 1.433 0.841 0.457 0.228 0.034 Anti-KAPPA12G3Rmb5 1.861 1.116 0.604 0.367 0.207 0.075 Anti-KAPPA12G3Rmb6 1.938 1.172 0.646 0.373 0.218 0.092

[0166] 3. Stability assessment

[0167] The above antibodies were placed at 4°C (refrigerator), -80°C (refrigerator), and 37°C (constant temperature box) for 21 days, and samples were taken for 7 days, 14 days, and 21 days for status observation, and the activity of the 21-day samples was tested. The results showed that there was no obvious protein state change in the antibodies under the three test conditions for 21 days, and the activity did not show a downward trend with the increase of the test temperature, indicating that the above antibodies are stable. Table 4 below shows the OD results of the enzyme immunoassay activity test of the antibody Anti-KAPPA 12G3Rmb3 for 21 days.

[0168] Table 4 Stability data

[0169] Sample concentration (ng / ml) 62.50 31.25 0.00 4℃, 21-day samples 1.447 0.836 0.027 -80℃, 21 days sample 1.452 0.845 0.026 37℃, 21 days sample 1.426 0.823 0.025

[0170] 4. Actual detection performance analysis

[0171] Any one of the antibodies Anti-KAPPA 12G3Rmb1 to Anti-KAPPA 12G3Rmb6 is paired with another antibody and used on a biochemical platform to analyze the performance of the antibody in actual detection.

[0172] The detection process includes: aspirating 1.5ul of the sample on the sample plate, and at the same time aspirating 200ul of R1 (Tris buffer), adding them into the cuvette, mechanically stirring, and incubating at 37°C for 5 minutes; adding 50ul of R2 (antibody-conjugated latex reagent) into the cuvette, mechanically stirring; the detection wavelength is 570nm, and the instrument records the absorbance values ​​at 7 minutes and 30 seconds and 12 minutes from the addition of the sample. The difference is the reactivity of the sample. The reactivity is proportional to the Kappa FLC concentration in the sample. The specific reactivity data are shown in the following table 5.

[0173] Table 5 Biochemical detection reaction data

[0174]

[0175] Note: The blank calibrator column refers to the background value detected when there is no sample, while the reaction data obtained at other calibrator concentrations are the reaction data after subtracting the background value.

[0176] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

[0177] Some of the amino acid sequences involved in this application are shown in Table 6:

[0178] Table 6 Amino Acid Sequence Listing

[0179]

[0180]

Claims

1. An anti-κ light chain antibody or an antigen-binding fragment thereof, comprising three complementary determining regions of a heavy chain variable region having an amino acid sequence of any one of SEQ ID NOs: 20 and 21 and three complementary determining regions of a light chain variable region having an amino acid sequence of any one of SEQ ID NOs: 24, 25, and 26.

2. The anti-κ light chain antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The complementarity determining regions of the variable regions are defined by any one of the Kabat, Chothia, IMGT, AbM or Contact systems or a combination of multiple systems.

3. An anti-κ light chain antibody or an antigen-binding fragment thereof, characterized in that: The anti-κ light chain antibody or antigen-binding fragment thereof comprises the following complementarity determining regions: HCDR1, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 1; HCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 2; HCDR3, which comprises or consists of the amino acid sequence shown in SEQ ID NO: 3; LCDR1, which comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 4 and 17; LCDR2, which comprises or consists of the amino acid sequence shown in SEQ ID NO:5; and LCDR3, which comprises or consists of the amino acid sequence shown in any one of SEQ ID NOs: 6 and 18; Optionally, the anti-κ light chain antibody or antigen-binding fragment thereof further has at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3 and LFR4; The HFR1 comprises SEQ ID NO:7 or an amino acid sequence having at least 80% identity thereto; The HFR2 comprises SEQ ID NO: 8 or an amino acid sequence having at least 80% identity thereto; The HFR3 comprises SEQ ID NO:9 or an amino acid sequence having at least 80% identity thereto; The HFR4 comprises SEQ ID NO: 10 or an amino acid sequence having at least 80% identity thereto; The LFR1 comprises SEQ ID NO: 11 or an amino acid sequence having at least 80% identity thereto; The LFR2 comprises SEQ ID NO: 12 or an amino acid sequence having at least 80% identity thereto; The LFR3 comprises SEQ ID NO: 13 or an amino acid sequence having at least 80% identity thereto; The LFR4 comprises SEQ ID NO: 14 or an amino acid sequence having at least 80% identity thereto.

4. An anti-κ light chain antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and / or a light chain variable region, characterized in that: The amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NOs: 20 and 21; the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NOs: 24, 25, and 26; Optionally, the combination of the heavy chain variable region and the light chain variable region is selected from any one of the following combinations: Optionally, the anti-κ light chain antibody or antigen-binding fragment thereof further comprises a constant region; Optionally, the constant region includes a heavy chain constant region and / or a light chain constant region; Optionally, the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments; Optionally, the heavy chain constant region includes CH1 of IgG, hinge region of IgG, CH2 of IgM, CH3 of IgM and / or CH4 of IgM; Optionally, the species of the constant region is cattle, horse, pig, sheep, goat, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose or human; Optionally, the species origin of the constant region is mouse; Optionally, the heavy chain constant region sequence is as shown in SEQ ID NO: 15 or has at least 80% identity thereto; Optionally, the light chain constant region sequence is as shown in SEQ ID NO: 16 or has at least 80% identity thereto; Optionally, the antigen-binding fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of the antibody.

5. An anti-κ light chain antibody or an antigen-binding fragment thereof, comprising a heavy chain and / or a light chain, characterized in that: The amino acid sequence of the heavy chain is shown in any one of SEQ ID NOs: 22 and 23; the amino acid sequence of the light chain is shown in any one of SEQ ID NOs: 27, 28, and 29.

6. An antibody conjugate, characterized in that: The antibody conjugate comprises the anti-κ light chain antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; Optionally, the antibody conjugate further comprises biotin or a biotin derivative coupled to the anti-κ type light chain antibody or antigen-binding fragment thereof; Optionally, the antibody conjugate further comprises a label coupled to the anti-κ light chain antibody or antigen-binding fragment thereof; Optionally, the label is selected from fluorescent dyes, enzymes, radioisotopes, chemiluminescent agents and nanoparticle labels; Optionally, the antibody conjugate further comprises a solid phase carrier coupled to the anti-κ type light chain antibody or antigen-binding fragment thereof; Optionally, the solid phase carrier is selected from microspheres.

7. A reagent or a kit, characterized in that: The reagent or kit comprises the anti-κ light chain antibody or antigen-binding fragment thereof according to any one of claims 1 to 5 or the antibody conjugate according to claim 6.

8. A method for detecting κ-type light chain, characterized in that: include: a) contacting the anti-κ light chain antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, the antibody conjugate according to claim 6, or the reagent or kit according to claim 7 with a κ light chain in a sample to be detected to form an immune complex under conditions sufficient for an antibody / antigen binding reaction to occur; and b) detecting the presence of the immune complex, the presence of the complex indicating the presence of the antigen in the test sample; Optionally, the immune complex further comprises a second antibody, which binds to the anti-κ light chain antibody or antigen-binding fragment thereof; Optionally, the immune complex further comprises a second antibody, which binds to a κ light chain.

9. A nucleic acid, a vector, a cell or a method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, characterized in that: The nucleic acid encodes the anti-κ light chain antibody or antigen-binding fragment thereof according to any one of claims 1 to 5; the vector contains the above-mentioned nucleic acid; the cell contains the above-mentioned nucleic acid or vector; and the method comprises culturing the above-mentioned cell.

10. Use of the anti-κ light chain antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, the antibody conjugate according to claim 6, or the reagent or kit according to claim 7 in the preparation of a product for detecting κ light chain.

Images